Patents by Inventor Serene Josiah
Serene Josiah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210163603Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular. Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.Type: ApplicationFiled: July 14, 2020Publication date: June 3, 2021Inventors: Serene Josiah, Thomas M. Luby, Atsushi Asakura, Dennis Keefe, Lawrence Charnas, Mayank Verma
-
Patent number: 10415039Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.Type: GrantFiled: January 6, 2017Date of Patent: September 17, 2019Assignee: Shire Human Genetic Therapies, Inc.Inventors: Stefan Stamm, Manli Shen, Serene Josiah
-
Publication number: 20180312593Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.Type: ApplicationFiled: April 12, 2018Publication date: November 1, 2018Inventors: Serene Josiah, Thomas M. Luby, Atsushi Asakura, Dennis Keefe, Lawrence Charnas, Mayank Verma
-
Patent number: 9957324Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.Type: GrantFiled: January 28, 2014Date of Patent: May 1, 2018Assignees: Shire Human Genetic Therapies, Inc., Regents of the University of MinnesotaInventors: Serene Josiah, Thomas M. Luby, Atsushi Asakura, Dennis Keefe, Lawrence Charnas, Mayank Verma
-
Patent number: 9932377Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: GrantFiled: January 12, 2016Date of Patent: April 3, 2018Assignee: Shire Human Genetic Therapies, Inc.Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Publication number: 20170335330Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.Type: ApplicationFiled: January 6, 2017Publication date: November 23, 2017Inventors: Stefan Stamm, Manli Shen, Serene Josiah
-
Patent number: 9567585Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.Type: GrantFiled: November 9, 2012Date of Patent: February 14, 2017Assignees: Shire Human Genetic Therapies, Inc., University of KentuckyInventors: Stefan Stamm, Manli Shen, Serene Josiah
-
Publication number: 20160237129Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: ApplicationFiled: January 12, 2016Publication date: August 18, 2016Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Patent number: 9260495Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: GrantFiled: June 15, 2012Date of Patent: February 16, 2016Assignee: Shire Human Genetic Therapies, Inc.Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Publication number: 20150361174Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.Type: ApplicationFiled: January 28, 2014Publication date: December 17, 2015Applicants: Shire Human Genetic Therapies, Inc., Regents of the University of MinnesotaInventors: Serene Josiah, Thomas M. Luby, Atsushi Asakura, Dennis Keefe, Lawrence Charnas
-
Publication number: 20140275222Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.Type: ApplicationFiled: November 9, 2012Publication date: September 18, 2014Applicants: Shire Human Genetic Therapies, Inc., University of KentuckyInventors: Stefan Stamm, Manli Shen, Serene Josiah
-
Publication number: 20140135275Abstract: The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.Type: ApplicationFiled: June 15, 2012Publication date: May 15, 2014Applicant: Shire Human Genetic Therapies, Inc.Inventors: Dennis Keefe, Michael Concino, Michael Heartlein, Serene Josiah, Bettina Strack-Logue
-
Patent number: 6146842Abstract: A high throughput enzyme screen has been developed which relies on metal chelate interaction for capture of the product of the enzymatic reaction. In the present assay system, a detectable moiety is attached to a substrate having a chelating capturable moiety, which can be captured by an immobilized metal. Detection is effected due to the presence of a detectable label on the reaction product immobilized on the solid phase. Only signal associated with tagged protein bound to the solid phase is detected. The present assay can reliably measure enzyme activity, and has high reproducibility, which benefits high throughput screening.Type: GrantFiled: September 17, 1999Date of Patent: November 14, 2000Assignee: Mitotix, Inc.Inventors: Serene Josiah, Michael Boisclair